索拉非尼治疗后经射频消融实现晚期肝细胞癌完全缓解
Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.
作者信息
Park Jung Gil, Park Soo Young, Lee Hye Won
机构信息
Jung Gil Park, Division of Gastroenterology and Hepatology, Department of Internal Medicine, CHA University, Gumi CHA Medical Center, Gumi 730-728, South Korea.
出版信息
World J Gastroenterol. 2015 Feb 28;21(8):2568-72. doi: 10.3748/wjg.v21.i8.2568.
Abstract
Sorafenib, a potent multikinase inhibitor, lead to a significant improvement in progression free survival and overall survival in patients with advanced hepatocellular carcinoma (HCC). Though sorafenib has proven its efficacy in advanced stage HCC, there are limited reports on the role of sorafenib allowing for curative treatment by down-staging. We herein report a case of advanced HCC with vascular invasion, which showed treatment response by sorafenib therapy as to allow for radiofrequency ablation as curative treatment. The patient was followed-up for 6 mo without recurrence with continued sorafenib therapy.
摘要
索拉非尼是一种强效多激酶抑制剂，可显著改善晚期肝细胞癌（HCC）患者的无进展生存期和总生存期。尽管索拉非尼已在晚期HCC中证明了其疗效，但关于索拉非尼通过降期实现根治性治疗作用的报道有限。我们在此报告一例伴有血管侵犯的晚期HCC病例，该病例显示索拉非尼治疗有反应，从而能够进行射频消融作为根治性治疗。该患者在继续索拉非尼治疗的情况下随访6个月无复发。
相似文献
1
Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.
World J Gastroenterol. 2015 Feb 28;21(8):2568-72. doi: 10.3748/wjg.v21.i8.2568.
2
Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
BMC Cancer. 2016 Nov 7;16(1):856. doi: 10.1186/s12885-016-2868-y.
3
Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.
Am J Gastroenterol. 2014 Dec;109(12):1891-9. doi: 10.1038/ajg.2014.343. Epub 2014 Nov 18.
4
Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Trials. 2014 Dec 3;15:474. doi: 10.1186/1745-6215-15-474.
5
Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review.
Exp Clin Transplant. 2018 Apr;16(2):227-236. doi: 10.6002/ect.2015.0299. Epub 2016 May 17.
6
Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.
Eur Rev Med Pharmacol Sci. 2015;19(2):247-55.
7
Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Future Oncol. 2015;11(16):2263-6. doi: 10.2217/fon.15.161.
8
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.
9
Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma.
Tunis Med. 2015 Jun;93(6):350-2.
10
Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma.
World J Gastroenterol. 2016 Nov 14;22(42):9445-9450. doi: 10.3748/wjg.v22.i42.9445.
引用本文的文献
1
An Investigation of Popping During Radiofrequency Ablation After Lenvatinib Administration for Hepatocellular Carcinoma.
In Vivo. 2023 Mar-Apr;37(2):836-840. doi: 10.21873/invivo.13150.
2
Pathological complete response by advanced hepatocellular carcinoma with massive macrovascular invasion to hepatic arterial infusion chemotherapy: a case report.
World J Surg Oncol. 2019 Dec 26;17(1):229. doi: 10.1186/s12957-019-1772-8.
3
Notch1 regulates the JNK signaling pathway and increases apoptosis in hepatocellular carcinoma.
Oncotarget. 2017 Jul 11;8(28):45837-45847. doi: 10.18632/oncotarget.17434.
4
(125)I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma.
World J Gastroenterol. 2016 Jun 7;22(21):5033-41. doi: 10.3748/wjg.v22.i21.5033.
本文引用的文献
1
Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report.
World J Gastrointest Oncol. 2013 Feb 15;5(2):38-42. doi: 10.4251/wjgo.v5.i2.38.
2
Multidisciplinary management of hepatocellular carcinoma: where are we today?
Semin Liver Dis. 2013 Feb;33 Suppl 1:S3-10. doi: 10.1055/s-0033-1333631. Epub 2013 Mar 1.
3
Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy.
Dig Dis Sci. 2013 May;58(5):1428-32. doi: 10.1007/s10620-012-2522-8. Epub 2013 Jan 10.
4
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
J Hepatol. 2012 Jul;57(1):101-7. doi: 10.1016/j.jhep.2012.02.016. Epub 2012 Mar 10.
5
Overview: Where does radiation therapy fit in the spectrum of liver cancer local-regional therapies?
Semin Radiat Oncol. 2011 Oct;21(4):241-6. doi: 10.1016/j.semradonc.2011.05.009.
6
Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.
J Clin Oncol. 2011 Oct 20;29(30):3960-7. doi: 10.1200/JCO.2011.37.1021. Epub 2011 Sep 12.
7
Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.
Liver Int. 2011 May;31(5):740-3. doi: 10.1111/j.1478-3231.2010.02441.x. Epub 2011 Jan 11.
8
Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.
J Clin Oncol. 2011 Apr 20;29(12):e330-2. doi: 10.1200/JCO.2010.32.6785. Epub 2011 Jan 24.
9
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
JAMA. 2010 Nov 17;304(19):2154-60. doi: 10.1001/jama.2010.1672.
10
Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation.
J Gastrointest Cancer. 2011 Mar;42(1):50-3. doi: 10.1007/s12029-010-9196-2.
Zotero 插件